

(Translation)

August 28, 2024

Company name: Riken Vitamin Co., Ltd.
Name of representative: Kazuhiko Yamaki
President and Representative Director
(Securities code: 4526; Tokyo Stock
Exchange Prime Market)
Inquiries: Yuichi Nakagawa
General Manager of Corporate Planning
Department, Chief Manager of Corporate
Planning Division
(Tel: 03-5362-1315)

Notice Regarding Establishment of Subsidiaries

Riken Vitamin Co., Ltd. (the “Company”) hereby announces that its Board of Directors, at a meeting held today, resolved to establish subsidiaries in the Kingdom of Thailand (“Thailand”) and the Socialist Republic of Viet Nam (“Vietnam”).

1. Purpose of Establishment of the Subsidiaries

One of the basic policies of the Company’s current medium-term management plan (FY2022-2024) is to “Accelerate expansion in Asia and North America”. Based on this policy, RIKEVITA (SINGAPORE) PTE LTD (“RIKEVITA (SINGAPORE)”), the Company’s wholly-owned subsidiary based in the Republic of Singapore, has been expanding sales of improving agents in Southeast Asia. The Company has decided to establish subsidiaries in Thailand, where market needs are becoming more diverse and sophisticated, and Vietnam, where the market is expected to expand in line with economic growth, to further strengthen its sales capabilities.

2. Overview of the Subsidiaries

(1) Name	RIKEVITA THAILAND CO., LTD. (planned)	RIKEVITA VIETNAM CO., LTD. (planned)
(2) Location	Bangkok, Thailand	Ho Chi Minh City, Vietnam
(3) Representative	Taiji Nagano	Taiji Nagano
(4) Description of businesses	Sales of Food-improving agents and Chemical-improving agents	Sales of Food-improving agents and Chemical-improving agents
(5) Share capital	10 million baht (approximately 42 million yen) (planned)	3 billion dong (approximately 17 million yen) (planned)
(6) Date of incorporation	January 2025 (scheduled)	January 2025 (scheduled)
(7) Major shareholders and shareholding ratio	RIKEVITA (SINGAPORE): 60% The Company: 40%	RIKEVITA (SINGAPORE): 60% The Company: 40%

3. Outlook

The impact of the establishment of the subsidiaries on the Company’s consolidated financial results for the fiscal year ending March 2025 is expected to be negligible. If any matters requiring disclosure arise in the future, the Company will disclose them promptly.